Advertisement

Breast Cancer Research and Treatment

, Volume 147, Issue 2, pp 401–405 | Cite as

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

  • T. Byrski
  • T. Huzarski
  • R. Dent
  • E. Marczyk
  • M. Jasiowka
  • J. Gronwald
  • J. Jakubowicz
  • C. Cybulski
  • R. Wisniowski
  • D. Godlewski
  • J. Lubinski
  • S. A. Narod
Epidemiology

Abstract

The aim of this study is to estimate the frequency of pathologic complete response (pCR) after neoadjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation. One hundred and seven women with breast cancer and a BRCA1 mutation, who were diagnosed with stage I to III breast cancer between December 2006 and June 2014, were treated with cisplatin 75 mg/m2 every 3 weeks for four cycles, followed by mastectomy and conventional chemotherapy. Information was collected on clinical stage, grade, hormone receptor status, and Her2neu status prior to treatment. pCR was determined by review of surgical specimens. One hundred and seven patients were enrolled in the study, including 93 patients who were treated for first primary breast cancer and 14 patients who had previously received treatment for a prior cancer. A pCR was observed in 65 of the 107 patients (61 %). Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancer.

Keywords

BRCA1 Breast cancer Neoadjuvant cisplatin 

Notes

Acknowledgments

We would like to thank M. Siolek, M. Szwiec, H. Symonowicz, D. Surdyka, O. Ashuryk, B. Gorski, T. Debniak, D. Zuziak, and D. Sawka for helping to recruit patients to this study. We thank W. Domagala for the pathology review. We would also like to thank the Estee Lauder companies for their generous support on this project. The study is registered in the Clinical Trails gov, study number NCT01630226 and was by funded by Polish Ministry of Science; Grant No. PBZ-KBN-122 /po5/ 2004.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 10:1275–1281CrossRefGoogle Scholar
  2. 2.
    Scully R, Ganesan S, Vlasakova K et al (1999) Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 4:1093–1099PubMedCrossRefGoogle Scholar
  3. 3.
    Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285–1291PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145PubMedCrossRefGoogle Scholar
  5. 5.
    Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034PubMedCrossRefGoogle Scholar
  6. 6.
    Tilanus-Linthorst MM, Obdeijn IM, Hop WC et al (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13:7357–7362PubMedCrossRefGoogle Scholar
  7. 7.
    Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115–123PubMedCrossRefGoogle Scholar
  9. 9.
    Narod SA, Metcalfe K, Lynch HT et al (2013) Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat 138:273–279PubMedCrossRefGoogle Scholar
  10. 10.
    Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659–1668PubMedCrossRefGoogle Scholar
  11. 11.
    Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 6319:6221–6228Google Scholar
  12. 12.
    Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899–23903PubMedCrossRefGoogle Scholar
  13. 13.
    Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F (2003) BRCA1 down-regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5:1001–1007CrossRefGoogle Scholar
  14. 14.
    Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379PubMedCrossRefGoogle Scholar
  15. 15.
    Górski B, Jakubowska A, Huzarski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686PubMedCrossRefGoogle Scholar
  16. 16.
    NCI (2003) National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), version 3, June 10, 2004 update. Bethesda, MD, National Cancer Institute, National Institutes of HealthGoogle Scholar
  17. 17.
    von Minckwitz G, Schneeweiss A, Loibl S (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15:747–756CrossRefGoogle Scholar
  18. 18.
    Sikov WM, Berry DA, Perou CM, Singh B, et al (2013) Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). In: San Antoniou Breast Cancer Conference 2013 (abstracts S-501)Google Scholar
  19. 19.
    Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145–1153PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Mazouni C, Kau SW, Frye D et al (2007) Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18:874–880PubMedCrossRefGoogle Scholar
  21. 21.
    Huzarski T, Byrski T, Gronwald J et al (2013) Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31:3191–3196. doi: 10.1200/JCO.2012.45.3571 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • T. Byrski
    • 1
  • T. Huzarski
    • 2
  • R. Dent
    • 3
  • E. Marczyk
    • 4
  • M. Jasiowka
    • 4
  • J. Gronwald
    • 2
  • J. Jakubowicz
    • 4
  • C. Cybulski
    • 2
  • R. Wisniowski
    • 5
  • D. Godlewski
    • 6
  • J. Lubinski
    • 2
  • S. A. Narod
    • 7
  1. 1.Department of OncologyInternational Hereditary Cancer Center, Pomeranian Medical UniversitySzczecinPoland
  2. 2.Department of Genetics and PathologyInternational Hereditary Cancer Center, Pomeranian Medical UniversitySzczecinPoland
  3. 3.Sunnybrook Odette Cancer CenterTorontoCanada
  4. 4.Oncology InstituteKrakówPoland
  5. 5.Regional Oncology CenterBielsko-BialaPoland
  6. 6.Center for Epidemiology and PreventionPoznanPoland
  7. 7.Women’s College Research InstituteTorontoCanada

Personalised recommendations